Observational studyBlood cancer journal2020
Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis.
Observational study in Blood cancer journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review.Clinical lymphoma, myeloma & leukemia · 2023Pooled it
- Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies.JCO global oncology · 2022Pooled it
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.Blood advances · 2021Trial
- Evolution of real-world frontline treatment patterns in multiple myeloma.Blood advances · 2026Article
- Moving Mountains: Improving Access to Autologous Stem Cell Transplant for Vulnerable Patient Populations.Cancers · 2026Article
- Analysis of Social Drivers of Health, Race, and Ethnicity With Survival in Myeloma Patients.Clinical lymphoma, myeloma & leukemia · 2026Article
- Investigating CAR-T Treatment Access for Multiple Myeloma Patients Using Real-World Evidence.Cancers · 2026Article
- Racial disparities in multiple myeloma: biological heterogeneity, treatment access, and prognostic implications.Leukemia & lymphoma · 2026Review
- Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans.Blood cancer journal · 2025Article
- Article
- Impact of social determinants of health on treatment patterns and outcomes in multiple myeloma.Future oncology (London, England) · 2025Article
- Comparison of outcomes by race among a population-based matched sample of multiple myeloma patients.Cancer causes & control : CCC · 2025Article
- Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma.Blood neoplasia · 2025Article
- Application of radiomics model based on FDG-PET/CT for the assessment of therapeutic effect in patients with newly-diagnosed multiple myeloma.Frontiers in oncology · 2025Article
- Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.Blood cancer journal · 2024Article
- Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.Blood cancer journal · 2024Article
- Role of Patient Characteristics and Insurance Type in Newly Diagnosed Multiple Myeloma Care Disparities.JCO oncology practice · 2024Article
- Impact of race and ethnicity on early mortality in multiple myeloma: a SEER analysis.Haematologica · 2024Article
- "They don't care to study it": Trust, race, and health care experiences among patient-caregiver dyads with multiple myeloma.Cancer medicine · 2024Article
- Racial differences in treatment and survival among older patients with multiple myeloma.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Findings on racial differences in survival in multiple myeloma (MM) have been inconclusive. We assessed differences in outcomes between White and Black individuals among 639 newly diagnosed MM patients in the MM Research Foundation CoMMpass registry with baseline cytogenetic data. Survival curves were constructed using the Kaplan-Meier method. Hazard ratios and 95% confidence intervals were derived from Cox proportional hazard regression models. Age, gender, and stage were similar between Whites (n = 526) and Blacks (n = 113). Blacks had inferior overall survival (OS) compared with Whites and were less likely to receive triplet therapies or frontline autologous stem cell transplant (ASCT). The following factors were significantly associated with inferior OS in multivariate analysis: higher international staging system (ISS) score, ≥1 or ≥2 high-risk cytogenetic abnormalities (HRCA), high-risk gene expression profile (GEP), and lack of ASCT. Multivariate analysis in the Black subset found that only lack of ASCT was significantly associated with inferior OS. The receipt of both triplet induction and ASCT only partly abrogated the effect of race on survival. HRCA did not track with survival in Blacks, emphasizing the need for race-specific risk prognostication schema to guide optimal MM therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.